文献速递急性肾损伤肾血管病与高血压

血管生物标志物sFlt-1与PlGF在硬皮病肾危象中的诊断性能初探

Pilot Study of Diagnostic Performances of Vascular Biomarkers Soluble fms-Like Tyrosine Kinase and Placental Growth Factor in Scleroderma Renal Crisis.
PubMed 文献 · Kidney Int Rep · 2024-12-31

本研究回顾性评估血管生成分子PlGF、sFlt-1及sFlt1/PlGF比值在硬皮病肾危象(SRC)中的诊断与预后价值。SRC患者血清PlGF显著高于供者、无SRC的SSc患者、HUS及恶性高血压患者,PlGF>24.5 pg/ml诊断SRC的AUC为0.81、特异性95%、敏感性67%,且与长期透析风险相关。

要点

  • SRC患者血清PlGF显著高于无SRC的SSc、HUS、恶性高血压及供者。
  • PlGF>24.5 pg/ml诊断SRC的AUC为0.81,特异性95%,敏感性67%。
  • SRC患者中PlGF较高者发生终末期肾衰竭的风险更高。

核心结论

  • 血清PlGF可能以较高特异性识别SSc患者发生SRC的风险,并可能用于评估长期透析风险。

研究设计与样本

  • 回顾性研究,收集27例有SRC病史的SSc患者血清,与年龄性别匹配的24例无SRC的SSc、27例溶血性尿毒症综合征、22例恶性高血压及61例供者比较。

主要发现

  • SSc-SRC+患者PlGF中位数42.1 pg/ml,显著高于供者14.7、SSc-SRC- 18.5、HUS 22.8及MHT 25.5 pg/ml(P<0.0001)。
  • 多因素回归中PlGF与SRC风险升高相关,OR为1.08(95%CI 1.01-1.22),P=0.034。
  • PlGF>24.5 pg/ml诊断SRC的AUC为0.81(95%CI 0.68-0.94),特异性95%,敏感性67%。
  • 11例SSc-SRC+患者达到终末期肾衰竭,其PlGF为42.9 pg/ml,显著高于未透析患者的19.7 pg/ml(P=0.03)。

关键数值与推荐

  • PlGF>24.5 pg/ml作为SRC诊断阈值时,AUC 0.81(95%CI 0.68-0.94),特异性95%,敏感性67%。
  • 多因素回归中PlGF每单位升高与SRC风险的OR为1.08(95%CI 1.01-1.22),P=0.034。

临床怎么用

  • 对SSc患者可考虑检测血清PlGF辅助识别SRC风险,高PlGF水平提示需关注长期透析风险。

局限性

  • 回顾性研究,样本量较小,SRC患者血清采集于事件发生后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. In this retrospective study, we evaluated the potential prognostic and diagnostic roles of angiogenesis molecules, placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1) and sFlt1/PlGF ratio as biomarkers in SRC. METHODS: Sera samples from 27 patients with a history of SRC (SSc-SRC+) were collected following event occurence. Biomarker levels were assessed using an electrochemiluminescence immunoassay and compared with age- and sex-matched patients with SSc-SRC- (n = 24), hemolytic uremic syndrome (HUS) (n = 27), malignant hypertension (MHT) (n = 22), and donors (n = 61). Areas under the receiver-operating-characteristic curves (AUC) were used to evaluate diagnostic accuracy. Long-term dialysis risk was evaluated using a Cox model. RESULTS: The median (interquartile range [IQR]) PlGF (pg/ml) was significantly higher in the serum of patients with SSc-SRC+ (42.1 [21.4-51.8]) compared with donors (14.7 [11.8-17.9]), those with SSc-SRC- (18.5 [14.7-21.5]) (P < 0.0001), those with HUS (22.8 [19.5-29.6]), and those with MHT (25.5 [17.2-39.3]) (P < 0.0001). In a multivariate regression adjusting for multiple confounders, PlGF was associated with higher SRC risk with an odds ratio of 1.08 [1.01-1.22], (P = 0.034). A PlGF level above 24.5 pg/ml revealed an AUC of 0.81 (confidence interval [0.68-0.94]), a specificity of 95%, and a sensitivity of 67% for SRC diagnosis. Eleven patients with SSc-SRC+ reached end-stage kidney failure with significantly higher PlGF (42.9 [22.4-78.2]) compared with patients who were dialysis-free (19.7 [15.6-29.7], P = 0.03). CONCLUSION: Serum PlGF may identify the risk of SRC occurrence among patients with SSc with a good specificity and represents a potential tool for long-term dialysis risk evaluation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kante A, Legendre P, Joly BS, et al. Pilot Study of Diagnostic Performances of Vascular Biomarkers Soluble fms-Like Tyrosine Kinase and Placental Growth Factor in Scleroderma Renal Crisis. Kidney Int Rep. 2024. PMID: 40225361. doi:10.1016/j.ekir.2024.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。